Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.
Hepatitis C virus (HCV) infection is associated with lymphoproliferative disorders and B-cell non-Hodgkin lymphomas (B-NHLs). Evaluation of the efficacy and safety profiles of different antiviral therapies in HCV patients with B-NHL is warranted.First, we evaluated the sustained virologic response (...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5066969?pdf=render |
| _version_ | 1819260385765621760 |
|---|---|
| author | Laurent Alric Caroline Besson Nathanael Lapidus Juliette Jeannel Jean-Marie Michot Patrice Cacoub Danielle Canioni Stanislas Pol Frédéric Davi Pascaline Rabiega Loic Ysebaert Delphine Bonnet Olivier Hermine |
| author_facet | Laurent Alric Caroline Besson Nathanael Lapidus Juliette Jeannel Jean-Marie Michot Patrice Cacoub Danielle Canioni Stanislas Pol Frédéric Davi Pascaline Rabiega Loic Ysebaert Delphine Bonnet Olivier Hermine |
| author_sort | Laurent Alric |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) infection is associated with lymphoproliferative disorders and B-cell non-Hodgkin lymphomas (B-NHLs). Evaluation of the efficacy and safety profiles of different antiviral therapies in HCV patients with B-NHL is warranted.First, we evaluated the sustained virologic response (SVR) and safety of Peg-interferon-alpha (Peg-IFN) + ribavirin +/- first protease inhibitors (PI1s) therapy in 61 HCV patients with B-NHL enrolled in a nationwide observational survey compared with 94 matched HCV-infected controls without B-NHL. In a second series, interferon-free regimens using a newly optimal combination therapy with direct-acting antiviral drugs (DAAs) were evaluated in 10 patients with HCV and B-NHL.The main lymphoma type was diffuse large B-cell lymphoma (38%) followed by marginal zone lymphoma (31%). In the multivariate analysis, patients with B-NHL treated by Peg-IFN-based therapy exhibited a greater SVR rate compared with controls, 50.8% vs 30.8%, respectively, p<0.01, odds ratio (OR) = 11.2 [2.3, 52.8]. B-NHL response was better (p = 0.02) in patients with SVR (69%) than in patients without SVR (31%). Premature discontinuation of Peg-IFN-based therapy was significantly more frequent in the B-NHL group (19.6%) compared with the control group (6.3%), p<0.02. Overall, survival was significantly enhanced in the controls than in the B-NHL group (hazard ratio = 34.4 [3.9, 304.2], p< 0.01). Using DAAs, SVR was achieved in 9/10 patients (90%). DAAs were both well tolerated and markedly efficient.The virologic response of HCV-associated B-NHL is high. Our study provides a comprehensive evaluation of different strategies for the antiviral treatment of B-NHL associated with HCV infection. |
| first_indexed | 2024-12-23T19:25:04Z |
| format | Article |
| id | doaj.art-72e5468689384192ae49396a9dc5768d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T19:25:04Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-72e5468689384192ae49396a9dc5768d2022-12-21T17:34:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011110e016296510.1371/journal.pone.0162965Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.Laurent AlricCaroline BessonNathanael LapidusJuliette JeannelJean-Marie MichotPatrice CacoubDanielle CanioniStanislas PolFrédéric DaviPascaline RabiegaLoic YsebaertDelphine BonnetOlivier HermineHepatitis C virus (HCV) infection is associated with lymphoproliferative disorders and B-cell non-Hodgkin lymphomas (B-NHLs). Evaluation of the efficacy and safety profiles of different antiviral therapies in HCV patients with B-NHL is warranted.First, we evaluated the sustained virologic response (SVR) and safety of Peg-interferon-alpha (Peg-IFN) + ribavirin +/- first protease inhibitors (PI1s) therapy in 61 HCV patients with B-NHL enrolled in a nationwide observational survey compared with 94 matched HCV-infected controls without B-NHL. In a second series, interferon-free regimens using a newly optimal combination therapy with direct-acting antiviral drugs (DAAs) were evaluated in 10 patients with HCV and B-NHL.The main lymphoma type was diffuse large B-cell lymphoma (38%) followed by marginal zone lymphoma (31%). In the multivariate analysis, patients with B-NHL treated by Peg-IFN-based therapy exhibited a greater SVR rate compared with controls, 50.8% vs 30.8%, respectively, p<0.01, odds ratio (OR) = 11.2 [2.3, 52.8]. B-NHL response was better (p = 0.02) in patients with SVR (69%) than in patients without SVR (31%). Premature discontinuation of Peg-IFN-based therapy was significantly more frequent in the B-NHL group (19.6%) compared with the control group (6.3%), p<0.02. Overall, survival was significantly enhanced in the controls than in the B-NHL group (hazard ratio = 34.4 [3.9, 304.2], p< 0.01). Using DAAs, SVR was achieved in 9/10 patients (90%). DAAs were both well tolerated and markedly efficient.The virologic response of HCV-associated B-NHL is high. Our study provides a comprehensive evaluation of different strategies for the antiviral treatment of B-NHL associated with HCV infection.http://europepmc.org/articles/PMC5066969?pdf=render |
| spellingShingle | Laurent Alric Caroline Besson Nathanael Lapidus Juliette Jeannel Jean-Marie Michot Patrice Cacoub Danielle Canioni Stanislas Pol Frédéric Davi Pascaline Rabiega Loic Ysebaert Delphine Bonnet Olivier Hermine Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLoS ONE |
| title | Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. |
| title_full | Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. |
| title_fullStr | Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. |
| title_full_unstemmed | Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. |
| title_short | Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. |
| title_sort | antiviral treatment of hcv infected patients with b cell non hodgkin lymphoma anrs hc 13 lympho c study |
| url | http://europepmc.org/articles/PMC5066969?pdf=render |
| work_keys_str_mv | AT laurentalric antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT carolinebesson antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT nathanaellapidus antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT juliettejeannel antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT jeanmariemichot antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT patricecacoub antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT daniellecanioni antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT stanislaspol antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT fredericdavi antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT pascalinerabiega antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT loicysebaert antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT delphinebonnet antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy AT olivierhermine antiviraltreatmentofhcvinfectedpatientswithbcellnonhodgkinlymphomaanrshc13lymphocstudy |